OSADENT 3.8 mg/1 g+ 3.8 mg/1 g+ 0.8 mg/1 g+ 0.8 mg/1 g+ 0.8 mg/1 g pilule Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

osadent 3.8 mg/1 g+ 3.8 mg/1 g+ 0.8 mg/1 g+ 0.8 mg/1 g+ 0.8 mg/1 g pilule

viennapharm d.o.o. - kalcijumfosfat, kalcijumkarbonat, kamilica, magnezijumfosfat, željezofosfat - pilule - 3.8 mg/1 g+ 3.8 mg/1 g+ 0.8 mg/1 g+ 0.8 mg/1 g+ 0.8 mg/1 g - 1 g pilula sadrži: chamomila recutita d6 3,8 mg + calcium phosphoricum d12 3,8 mg + magnesium phosphoricum c6 0,8 mg + calcium carbonicum hahnemanni dil. c8 0,8 mg + ferrum phosphoricum c8 0,8 mg

Kapruvia Europska Unija - hrvatski - EMA (European Medicines Agency)

kapruvia

vifor fresenius medical care renal pharma france - difelikefalin - pruritus - svi ostali terapeutski proizvodi - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.

Tybost Europska Unija - hrvatski - EMA (European Medicines Agency)

tybost

gilead sciences ireland uc - кобицистат - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Faxiven 37,5 mg kapsule s produljenim oslobađanjem Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

faxiven 37,5 mg kapsule s produljenim oslobađanjem

jadran galenski laboratorij d.d., svilno 20, rijeka - venlafaxinum - kapsula s produljenim oslobađanjem, tvrda - 37,5 mg - urbroj: jedna kapsula s produljenim olsobađanjem sadrži 37,5 mg venlafaksina u obliku venlafaksinklorida

M-M-RVaxPro Europska Unija - hrvatski - EMA (European Medicines Agency)

m-m-rvaxpro

merck sharp & dohme b.v.  - virus ospica soj edmonston enders' (živa, progib), virusa паротита jeryl lynn u (razina b) soja (živa, progib), virus rubeole Вистар ra 27/3 soj (živa, progib) - rubella; mumps; immunization; measles - cjepiva - m-m-rvaxpro dizajniran za simultano cijepljenje protiv ospica, паротита i rubeole kod osoba od 12 mjeseci i stariji. za uporabu bljeskalice ospica, ili za постконтактной cijepljenja, ili za uporabu u prethodno непривитым djeca starija od 12 mjeseci koji dolaze u kontakt s osjetljiv trudnice, kao i osobe koje mogu biti izloženi паротита i rubeole.

Spikevax (previously COVID-19 Vaccine Moderna) Europska Unija - hrvatski - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.